Subject
Clinical Neurology,Neurology,General Medicine
Reference22 articles.
1. Cancer risk for fingolimod, natalizumab, and rituximab in MS patients;Alping;Ann. Neurol.,2020
2. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial;Calabresi;Lancet Neurol.,2014
3. Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis;Chawanpaiboon;Lancet Glob Health,2019
4. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial;Cohen;Lancet Neurol.,2016
5. Efficacy and safety of ozanimod in multiple sclerosis: dose-blinded extension of a randomized phase II study;Cohen;Mult. Scler.,2019
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献